Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: Phase III study

Journal of the Medical Association of Thailand

Volumn 90, Issue 9, 2007, Pages 1720-1726

  Chandeying, Verapol ^a   Sangthawan, Malinee ^b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b HATYAI HOSPITAL   (Thailand)

Author keywords

Conjugated equine estrogen; Medroxyprogesterone acetate; Perimenopausal women; Phytoestrogen; Pueraria mirifica; Vasomotor symptoms

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; FOLLITROPIN; HERBACEOUS AGENT; LUTEINIZING HORMONE;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRY SKIN; DYSPAREUNIA; DYSURIA; EXCITABILITY; FATIGUE; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HEADACHE; HOT FLUSH; HUMAN; HYSTERECTOMY; INSOMNIA; LIBIDO DISORDER; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENTAL DISEASE; MENTAL INSTABILITY; NERVOUSNESS; NIGHT SWEAT; PREMENOPAUSE; PUERARIA; PUERARIA MIRIFICA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY FREQUENCY; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS;

ADULT; CLIMACTERIC; CONTRACEPTIVE AGENTS, FEMALE; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PERIMENOPAUSE; PHYTOESTROGENS; PROSPECTIVE STUDIES; PUERARIA; THAILAND;

EID: 35848931898     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36: 155-64.
2. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001; 13: 453-64.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
4. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
5. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
6. Nelson HD. Assessing benefits and harms of hormone replacement therapy: clinical applications. JAMA 2002; 288: 882-4.
7. Chivapat S, Chavalittumrong P, Rattanajarasroj S, Chuthaputti A, Panyamang S. Subchronic toxicity study of PM Airy Shaw et Suvatabandhu. Technical Report. Nonthaburi: Medicinal Herb Research Institute, Department of Medical Sciences, Ministry of Public Health, Thailand, 1999.
8. Lamlertkittikul S, Chandeying V. Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study. J Med Assoc Thai 2004; 87: 33-40.
9. Greene JG. A factor analytic study of climacteric symptoms. J Psychosom Res 1976; 20: 425-30.
10. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-76.
11. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 1999; 130: 897-904.
12. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065-79.
13. Bounds DG, Pope GS. Light-absorption and chemical properties of miroestrol, the oestrogenic substance of Pueraria mirifica. J Chem Soc 1960; 3696-705.
14. Scholler W, Dohrn M, Hohlweg W. An estrogenic substance from the tubes of Siamese vine, Butea superba. Naturwissenschaffen 1940;28:532.
15. Jones HE, Pope GS. A method for the isolation of miroestrol from Pueraria mirifica. J Endocrinol 1961; 22: 303-12.
16. th, Bangkok, Thailand 1957; 5: 37.
17. Chansakaow S, Ishikawa T, Seki H, Sekine nY, Okada M, Chaichantipyuth C. Identification of deoxymiroestrol as the actual rejuvenating principle of "Kwao Keur", Pueraria mirifica. The known miroestrol may be an artifact. J Nat Prod 2000; 63: 173-5.
18. th Conference of Science and Technology of Thailand, Bangkok, Thailand; 24-26 October 1985: 338.
19. Cain JC. Miroestrol: an oestrogen from the plant Pueraria mirifica. Nature 1960; 188: 774-7.
20. Pope GS. Estrogenic substances. Patent Brit 1957; 758: 987.
21. Sornsrivichai J, Liawruangrath S, Kittakupt P, Liawruangrath B, Smitasiri Y. Pharmacological aspects of oestrogenic substances in tuberous root of Pueraria mirifica. Abstr Princess Congress I, Bangkok, Thailand; 10-13 December 1987: 498.
22. Smitasiri Y, Liawruangrath S, Kittakupt P, Liawruangrath B, Sornsrivichai J. Pharmacological aspects of toxic substances in tuberous root of Pueraria mirifica. Abstr Princess Congress I, Bangkok, Thailand; 10-13 December 1987; 123.
23. th Conference of Science and Technology of Thailand, Bangkok, Thailand; 24-26 October 1985: 340.
24. th Conference of Science and Technology of Thailand, Bangkok, Thailand; 24-26 October 1985: 334.
25. th Conference of Science and Technology of Thailand, Bangkok, Thailand; 24-26 October 1985: 238.
26. Smitasiri Y, Junyatum U, Songjitsawad A. Post-coital antifertility effects of Pueraria mirifica in rats. J Sci Fac CMU 1986; 13: 19-28.
27. Smitasiri Y, Pangchitt S, Anuntalabhochai S. Inhibition of lactation in lactating rats with Pueraria mirifica comparison with estrogen. J Sci Fac CMU 1989; 16: 7-11.